<?xml version="1.0" encoding="UTF-8"?>
<p>Convalescent plasma or immunoglobulins have been shown to improve the survival rate of SARS patients with progressive deterioration.
 <xref rid="jcmm15364-bib-0095" ref-type="ref">
  <sup>95</sup>
 </xref> In the pandemic of 2009 influenza A H1N1 (H1N1pdm09) infection, convalescent plasma therapy was found to help to reduce the relative risk of mortality significantly.
 <xref rid="jcmm15364-bib-0096" ref-type="ref">
  <sup>96</sup>
 </xref> During the outbreak of Ebola virus disease (EVD) in 2014, the use of convalescent plasma collected from EVD recovery patients was recommended by WHO as one of the treatment modalities.
 <xref rid="jcmm15364-bib-0097" ref-type="ref">
  <sup>97</sup>
 </xref> In 2015, the laboratory effect of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection was reported
 <xref rid="jcmm15364-bib-0098" ref-type="ref">
  <sup>98</sup>
 </xref> and no severe adverse events occurred among those patients cured by convalescent plasma. An in vivo study also showed that the effects of this antibody were not only limited to free viral clearance and block new infection, but also could accelerate the clearance of infected cells.
 <xref rid="jcmm15364-bib-0099" ref-type="ref">
  <sup>99</sup>
 </xref>
</p>
